Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

NCT01087749
View directory record Official record
Conditions
Kidney Disease
Interventions
Propranolol, Losartan, Eprosartan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Results available

First in Human Study of M4344 in Participants With Advanced Solid Tumors

NCT02278250
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor
Interventions
M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 19, 2026, 11:13 PM EDT
Withdrawn Early Phase 1 Interventional

Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract

NCT03641248
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Enteric coated Devil's Claw, Non-enteric coated Devil's Claw
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 19, 2026, 11:13 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

NCT07349758
View directory record Official record
Conditions
Healthy Volunteer, HIV Prevention
Interventions
tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage

NCT00029315
View directory record Official record
Conditions
Cerebral Hemorrhage
Interventions
Recombinant Tissue Plasminogen Activator (rt-PA)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

NCT00675350
View directory record Official record
Conditions
Hematologic Tumors
Interventions
Omacetaxine
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 19, 2026, 11:13 PM EDT
Recruiting Phase 1 Interventional

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
Interventions
PT0511, Cetuximab
Drug
Lead sponsor
PAQ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Boston, Massachusetts • San Antonio, Texas • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of VHX-896 in Healthy Volunteers

NCT06803290
View directory record Official record
Conditions
Healthy
Interventions
VHX-896
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

NCT01074710
View directory record Official record
Conditions
Gastroparesis
Interventions
[2-13C] uracil, [2-13C] uracil, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT00864110
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study With Pravastatin and Cyclosporine

NCT01497483
View directory record Official record
Conditions
Healthy
Interventions
Pravastatin alone, Pravastatin and Cyclosporine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
HLD200 (methylphenidate hydrochloride)
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors

NCT01210846
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
tivozanib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Lafayette, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 19, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

NCT02134886
View directory record Official record
Conditions
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

NCT00644761
View directory record Official record
Conditions
Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2008 · Synced Oct 19, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03738423
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, REGN3500-Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

NCT01468688
View directory record Official record
Conditions
3rd Line GIST
Interventions
STI571, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of LY2886721 Single Doses in Healthy Subjects

NCT01133405
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2886721, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 19, 2026, 11:13 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic Study for IV Allopregnanolone

NCT04468360
View directory record Official record
Conditions
Pharmacokinetic Study, Post Traumatic Stress Disorder
Interventions
PK-1 Good Manufacturing Practices (GMP) allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis, PK-2 GMP allopregnanolone (Allo) with Dexolve in 0.9% saline for infusion manufactured by the University of California, Davis.
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

NCT04448561
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8082, morphine, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

NCT03235219
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ-64565111, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat in Treating Patients With Kidney Cancer

NCT00278395
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Vorinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 19, 2026, 11:13 PM EDT